Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Life Sciences
Research conducted at Hebei Medical University has provided new information about life sciences
November 26th, 2008
According to recent research from Shijiazhuang, People's Republic of China, "To rind a feasible method for the stimulation of tumor-draining lymph node (TDLN) cells in preparation for use in the clinic, the CTL activity of TDLN cells induced by different stimuli (IL-2 alone, IL-2 + autologous tumor antigen (atAg), IL-2 + GM-CSF + IL-4 + atAg) was measured by maximal LDH enzyme release. The mechanisms were explored by the observation of morphology and the detection of CD83(+) TDLN cells." "The expansion of TDLN cells by IL-2 + GM-CSF + IL-4 + atAg was significantly higher than that by IL-2 alone or IL-2 + atAg (p < 0.01). Antitumor CTL activity of TDLN cells induced...
Source: Immunotherapy Weekly (2008-11-26)
|
